Arrowstreet Capital
MRVI icon

Arrowstreet Capital’s Maravai LifeSciences MRVI Stock Holding History

Arrowstreet Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-357,781
Closed -$15M – 1425
2021
Q4 		$15M Buy
357,781
+134,137
+60% +$5.43M 0.02% 547
2021
Q3 		$11M Buy
+223,644
New +$10.9M 0.01% 716

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital's MRVI Position: Q1 2022 in Review

Arrowstreet Capital sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 357,781 shares — an estimated $15M sold.

Arrowstreet Capital first reported a position in MRVI in Q3 2021 and held it in 2 quarters. The position peaked at $15M in Q4 2021. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

  • Arrowstreet Capital reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
  • Arrowstreet Capital sold 357,781 Maravai LifeSciences shares in Q1 2022, an estimated $15M.
  • Arrowstreet Capital first reported a position in Maravai LifeSciences in Q3 2021 and held it in 2 quarters.
  • Arrowstreet Capital's Maravai LifeSciences position peaked at $15M in Q4 2021.
  • 235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on Arrowstreet Capital's 13F filing for Q1 2022, filed 13 May 2022.